Trial Profile
BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IMMhance
- Sponsors AbbVie; Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- 21 Mar 2023 Results of pooled analysis (n=1306 from four studies UltIMMa-1 and -2, IMMvent, and IMMhance) assessing racial and ethnic diversity for efficacy and safety outcomes presented at the American Academy of Dermatology annual Meeting 2023
- 25 Apr 2021 Results of an analysis assessing the efficacy and safety of Risankizumab re-treatment after withdrawal compared with continuous long-term Risankizumab treatment using data from the IMMhance and LIMMitless studies presented at the American Academy of Dermatology Virtual Meeting Experience 2021
- 25 Apr 2021 Results (n=2101) of post-hoc and pooled analysis of four phase III clinical trials (UltIMMa-1, UltIMMa-2, IMMvent, and IMMhance), presented at the American Academy of Dermatology Virtual Meeting Experience 2021.